Lineage Cell Therapeutics, Inc. announced that the results of imaging analyses demonstrating evidence of rapid improvement in outer retinal structure from a Phase 1/2a clinical study of RG6501 (OpRegen) ( Identifier: NCT02286089), which were reviewed by multiple, independent reviewers, will be presented at the 23rd EURETINA Congress. RG6501 (OpRegan) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD). OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.

It is being developed under an exclusive worldwide collaboration between Lineage, Roche, and Genentech, and is currently being evaluated in a Phase 2a clinical study in patients with GA secondary to AMD.